Investment Research Partners LLC Invests $928,000 in Gilead Sciences, Inc. $GILD

Investment Research Partners LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD) during the 3rd quarter, HoldingsChannel reports. The firm purchased 7,833 shares of the biopharmaceutical company’s stock, valued at approximately $928,000.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. acquired a new position in shares of Gilead Sciences during the third quarter valued at $24,418,000. Achmea Investment Management B.V. increased its holdings in shares of Gilead Sciences by 5.4% in the 3rd quarter. Achmea Investment Management B.V. now owns 480,352 shares of the biopharmaceutical company’s stock worth $53,319,000 after acquiring an additional 24,564 shares during the period. Centaurus Financial Inc. increased its holdings in shares of Gilead Sciences by 20.1% in the 3rd quarter. Centaurus Financial Inc. now owns 6,992 shares of the biopharmaceutical company’s stock worth $776,000 after acquiring an additional 1,168 shares during the period. First Affirmative Financial Network lifted its position in Gilead Sciences by 8.1% in the 3rd quarter. First Affirmative Financial Network now owns 3,672 shares of the biopharmaceutical company’s stock valued at $408,000 after purchasing an additional 276 shares during the last quarter. Finally, Asset Dedication LLC lifted its position in Gilead Sciences by 16.2% in the 3rd quarter. Asset Dedication LLC now owns 15,708 shares of the biopharmaceutical company’s stock valued at $1,744,000 after purchasing an additional 2,188 shares during the last quarter. Institutional investors and hedge funds own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Quarterly beat, raised guidance and dividend increase provide fundamental support — Gilead reported $1.86 EPS (vs. $1.83 est.), $7.93B revenue (vs. $7.68B est.), set FY‑2026 EPS guidance of $8.45–$8.85 and raised the quarterly dividend to $0.82. Those elements support longer‑term upside.
• Positive Sentiment: M&A/sector takeover chatter (Arcellx coverage) is reviving speculation that Gilead may pursue deals to bolster its cell‑therapy/oncology pipeline — a catalyst investors treat as strategic upside. Fool: Arcellx / takeover-related coverage
• Neutral Sentiment: Unusual options activity flagged by scanners — heightened option flow can signal hedging or speculative bets; it’s ambiguous until directional put/call skew and volume patterns solidify. Barchart: options activity
• Neutral Sentiment: Analysts show mixed/contrasting views — some firms have raised targets and reiterated buys while others are more cautious, so research flow is creating both support and headlines that can move sentiment. Globe and Mail: analysts conflicting
• Neutral Sentiment: New coverage of potential CAR‑T competitors (Estrella/ESLA) is worth watching but is not an immediate direct threat to Gilead’s larger, diversified franchise — more a sector development. Yahoo: ESLA coverage
• Negative Sentiment: Insider selling by senior executives — Johanna Mercier and CFO Andrew D. Dickinson each sold 3,000 shares (average ~$144.23) recently; multiple insider sales can sour near‑term sentiment even if part of planned diversification. InsiderTrades: insider sales
• Negative Sentiment: Recent headlines and retail coverage are bearish — pieces arguing to “avoid GILD” are amplifying outflows/weakness among some investors and may pressure the intraday move. Yahoo: 3 Reasons to Avoid GILD
• Negative Sentiment: Market‑coverage note reporting Gilead fell more than the broader market today — a short‑term confirmation of downward price pressure that may trigger additional technical selling. Zacks: GILD falls more than market

Analyst Ratings Changes

Several research analysts have commented on the stock. UBS Group upped their target price on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Truist Financial lifted their price target on Gilead Sciences from $145.00 to $152.00 and gave the company a “buy” rating in a report on Wednesday, February 11th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $110.00 to $115.00 and gave the stock a “neutral” rating in a research report on Thursday, January 8th. BMO Capital Markets raised their target price on Gilead Sciences from $135.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, January 26th. Finally, Rothschild & Co Redburn lifted their target price on Gilead Sciences from $159.00 to $170.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Twenty-four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $157.62.

Gilead Sciences Trading Down 2.2%

Shares of NASDAQ:GILD opened at $141.29 on Thursday. The company has a 50 day moving average of $141.96 and a 200-day moving average of $127.51. The firm has a market cap of $175.40 billion, a P/E ratio of 20.87, a P/E/G ratio of 1.89 and a beta of 0.37. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $157.29. The company has a current ratio of 1.55, a quick ratio of 1.40 and a debt-to-equity ratio of 0.98.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.83 by $0.03. Gilead Sciences had a net margin of 28.90% and a return on equity of 49.46%. The business had revenue of $7.93 billion during the quarter, compared to analysts’ expectations of $7.68 billion. During the same period last year, the firm posted $1.90 earnings per share. The business’s revenue was up 4.7% on a year-over-year basis. Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. As a group, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 30th. Stockholders of record on Friday, March 13th will be given a dividend of $0.82 per share. This is a boost from Gilead Sciences’s previous quarterly dividend of $0.79. The ex-dividend date is Friday, March 13th. This represents a $3.28 annualized dividend and a dividend yield of 2.3%. Gilead Sciences’s payout ratio is 48.45%.

Insider Transactions at Gilead Sciences

In other news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total value of $617,500.00. Following the sale, the director owned 8,920 shares of the company’s stock, valued at approximately $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Andrew D. Dickinson sold 3,000 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $144.23, for a total value of $432,690.00. Following the transaction, the chief financial officer directly owned 179,191 shares of the company’s stock, valued at $25,844,717.93. This represents a 1.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 309,280 shares of company stock worth $44,068,850 over the last 90 days. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.